Brought to you by 
Galena partners cancer immunotherapeutic NeuVax with Teva in Israel
16 Nov 2021
Executive Summary
Oncology company Galena Biopharma Inc. has licensed Teva Pharmaceutical Industries Ltd.’s Israeli division ABIC Marketing Ltd. exclusive rights to market its Phase III breast cancer immunotherapeutic NeuVax (nelipepimut-S) in Israel. Teva also received a right of first refusal on all other future indications.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Galena partners cancer immunotherapeutic NeuVax with Teva in Israel
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice